Nat Commun:打破认知!肿瘤坏死因子控制血压!

2017-04-09 生物谷 生物谷

来自泰德•罗杰斯心脏研究中心的研究人员发现了肿瘤坏死因子(TNF)的一个令人惊讶的新作用:它是小血管功能的主要调节因子,而小血管的功能是血液的关键决定因素。这项研究近日发表在Nature Communications上。长期以来,TNF都被认为与炎症相关,这也就催生了治疗慢性炎症疾病(如类风湿性关节炎、牛皮癣、肠易激综合症等)的抗

来自泰德•罗杰斯心脏研究中心的研究人员发现了肿瘤坏死因子(TNF)的一个令人惊讶的新作用:它是小血管功能的主要调节因子,而小血管的功能是血液的关键决定因素。这项研究近日发表在Nature Communications上。

长期以来,TNF都被认为与炎症相关,这也就催生了治疗慢性炎症疾病(如类风湿性关节炎、牛皮癣、肠易激综合症等)的抗TNF药物。但是研究人员在研究了TNF在血管系统中细胞信号通路上发挥的作用数年后,他们发现TNF可以直接影响最小的动脉的收缩,以此对血压造成了重要的影响。

“TNF的新功能为这个传统的细胞因子打上了新标签,使之成为了微动脉肌源性反应(心血管系统最著名、最重要的调节机制之一)的主要调节因子。”文章首席作者Jeff Kroetsch说道。

这是表明TNF可能帮助调节血压的第一个研究。Kroetsch及其同事发现TNF通过一种已知的、但并非传统的机制调节血管收缩。它不通过TNF受体激活传统的正向信号,反而通过启动反向信号直接传输到平滑肌细胞中进行调节。这是首次发现免疫系统之外的反向信号可以调节重要的生理过程。血管TNF的这个新功能在几种物种中都存在(包括人类),表明这种机制在进化过程中保守。

尽管是一项初期研究,但这项工作还是表明靶向TNF的抗炎症药物对血压控制有着负面影响,这对任何有心血管疾病(如心脏病)的患者而言都很危险。

“TNF的这种新功能表明使用抗TNF药物时要谨慎,因为它们可能会导致无法预料的血压反应,增加心血管压力。”泰德•罗杰斯心脏研究中心PI、多伦多大学生理学教授Steffen-Sebastian Bolz说道,“我们建议对使用抗TNF药物的病人进行监控,一旦出现血压紊乱,即刻停药。”

Kroetsch及其同事发现TNF在小的阻力动脉中扮演力学感受器的角色,可以感受血压的改变。随后TNF可以启动一系列生化过程影响血管的收缩。他们发现TNF控制着血压,同时干扰TNF信号的药物会显著降低血压。这项研究的意义可能不仅仅只限制于血管系统。

“由于TNF几乎在所有细胞中都表达,而这些细胞都对机械力敏感,因此这项发现可能也适用于心血管系统之外的其他组织和细胞。”Kroetsch说道,“未来的研究将探索身体中受TNF影响的其他重要过程。”

原文出处:

Jeffrey T. Kroetsch et al, Constitutive smooth muscle tumour necrosis factor regulates microvascular myogenic responsiveness and systemic blood pressure, Nature Communications (2017). DOI: 10.1038/ncomms14805

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881874, encodeId=ea9218818e4bd, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 29 16:42:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086982, encodeId=b07120869820a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Nov 08 07:42:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988327, encodeId=a388198832ec2, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Feb 11 08:42:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362821, encodeId=bb611362821fb, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 11 11:42:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485430, encodeId=07701485430de, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Tue Apr 11 11:42:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186441, encodeId=084918644185, content=涨知识学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Apr 10 16:51:17 CST 2017, time=2017-04-10, status=1, ipAttribution=)]
    2017-07-29 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1881874, encodeId=ea9218818e4bd, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 29 16:42:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086982, encodeId=b07120869820a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Nov 08 07:42:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988327, encodeId=a388198832ec2, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Feb 11 08:42:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362821, encodeId=bb611362821fb, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 11 11:42:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485430, encodeId=07701485430de, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Tue Apr 11 11:42:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186441, encodeId=084918644185, content=涨知识学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Apr 10 16:51:17 CST 2017, time=2017-04-10, status=1, ipAttribution=)]
    2017-11-08 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1881874, encodeId=ea9218818e4bd, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 29 16:42:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086982, encodeId=b07120869820a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Nov 08 07:42:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988327, encodeId=a388198832ec2, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Feb 11 08:42:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362821, encodeId=bb611362821fb, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 11 11:42:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485430, encodeId=07701485430de, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Tue Apr 11 11:42:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186441, encodeId=084918644185, content=涨知识学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Apr 10 16:51:17 CST 2017, time=2017-04-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1881874, encodeId=ea9218818e4bd, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 29 16:42:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086982, encodeId=b07120869820a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Nov 08 07:42:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988327, encodeId=a388198832ec2, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Feb 11 08:42:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362821, encodeId=bb611362821fb, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 11 11:42:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485430, encodeId=07701485430de, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Tue Apr 11 11:42:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186441, encodeId=084918644185, content=涨知识学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Apr 10 16:51:17 CST 2017, time=2017-04-10, status=1, ipAttribution=)]
    2017-04-11 millore
  5. [GetPortalCommentsPageByObjectIdResponse(id=1881874, encodeId=ea9218818e4bd, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 29 16:42:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086982, encodeId=b07120869820a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Nov 08 07:42:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988327, encodeId=a388198832ec2, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Feb 11 08:42:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362821, encodeId=bb611362821fb, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 11 11:42:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485430, encodeId=07701485430de, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Tue Apr 11 11:42:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186441, encodeId=084918644185, content=涨知识学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Apr 10 16:51:17 CST 2017, time=2017-04-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1881874, encodeId=ea9218818e4bd, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jul 29 16:42:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086982, encodeId=b07120869820a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Nov 08 07:42:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988327, encodeId=a388198832ec2, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Feb 11 08:42:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362821, encodeId=bb611362821fb, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 11 11:42:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485430, encodeId=07701485430de, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Tue Apr 11 11:42:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186441, encodeId=084918644185, content=涨知识学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Apr 10 16:51:17 CST 2017, time=2017-04-10, status=1, ipAttribution=)]
    2017-04-10 1ddf0692m34(暂无匿称)

    涨知识学习了

    0

相关资讯

JAMA:肿瘤坏死因子拮抗剂与癌症风险升高无关

丹麦一项队列研究纳入56146例年龄≥15岁的炎症性肠病(IBD)患者,并对肿瘤坏死因子(TNF-α)拮抗剂暴露是否升高患者的癌症风险进行评估。结果显示,中位3.7年随访期间,TNF-α拮抗剂暴露和未暴露患者的癌症发病率分别为1.8%和6.7%。依据自首次TNF-α拮抗剂暴露时间和用药次数进行分析时,癌症风险均未出现显著升高。部位特异性癌症亦未显著增多。论文发表于《美国医学会杂志》。

JAMA:对TNFα抑制剂反应不足的类风湿性关节炎患者或可选择非TNF生物制剂

三分之一的类风湿关节炎患者对肿瘤坏死因子α(TNFα)抑制剂的反应不足,缺少关于如何选择下一步治疗的指导。本研究旨在对比此类患者中靶向非肿瘤坏死因子的生物性药物与二抗肿瘤坏死因子药物的疗效。此多中心、实用性、开放标签的随机临床试验为期52周,2009-2012年间共有300名类风湿性关节炎患者,持续性疾病活动且对抗TNF治疗反应不足。最后的随访日期是2013年8月。将患者1:1随机分组分别接受非肿

Cell子刊:揭示肿瘤坏死因子抵抗感染新机制

作为免疫系统的一种信使分子,肿瘤坏死因子(tumor necrosis factor, TNF)在触发慢性炎症性疾病中发挥着重要作用。由于这个原因,TNF抑制剂是治疗类风湿性关节炎患者和某些炎症性肠病患者的一种标准方法。然而,TNF也防止感染,这意味着抑制它能够导致潜伏性感染重新露面。 如今,在一项新的研究中,来自德国埃朗根-纽伦堡大学(Friedrich-Alexander-Univ

Lupus:血清肿瘤坏死因子-α水平与系统性红斑狼疮患者的生活质量和抑郁症状相关

尽管系统性红斑狼疮(SLE)患者的健康相关的生活质量(HRQoL)比健康人更差,抑郁状态更严重,但是,重要促炎性细胞因子,比如,肿瘤坏死因子-α(TNF-α),对不良心理因素的重要性仍不清楚。针对这一情况,来自新加坡国立大学杨潞龄医学院风湿免疫科的A Mak等进行了一项研究。该研究的目的是探讨SLE患者抑郁症状,HRQoL和狼疮相关促炎性细胞因子有关。研究结果在线发布在2013年3月的《狼疮》(L